Prebiotic dietary fibre intervention improves fecal markers related to inflammation in obese patients: results from the Food4Gut randomized placebo-controlled trial
Open Access
- 5 February 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Nutrition
- Vol. 60 (6), 3159-3170
- https://doi.org/10.1007/s00394-021-02484-5
Abstract
Purpose Inulin-type fructans (ITF) are prebiotic dietary fibre (DF) that may confer beneficial health effects, by interacting with the gut microbiota. We have tested the hypothesis that a dietary intervention promoting inulin intake versus placebo influences fecal microbial-derived metabolites and markers related to gut integrity and inflammation in obese patients. Methods Microbiota (16S rRNA sequencing), long- and short-chain fatty acids (LCFA, SCFA), bile acids, zonulin, and calprotectin were analyzed in fecal samples obtained from obese patients included in a randomized, placebo-controlled trial. Participants received either 16 g/d native inulin (prebiotic n = 12) versus maltodextrin (placebo n = 12), coupled to dietary advice to consume inulin-rich versus inulin-poor vegetables for 3 months, in addition to dietary caloric restriction. Results Both placebo and prebiotic interventions lowered energy and protein intake. A substantial increase in Bifidobacterium was detected after ITF treatment (q = 0.049) supporting our recent data obtained in a larger cohort. Interestingly, fecal calprotectin, a marker of gut inflammation, was reduced upon ITF treatment. Both prebiotic and placebo interventions increased the ratio of tauro-conjugated/free bile acids in feces. Prebiotic treatment did not significantly modify fecal SCFA content but it increased fecal rumenic acid, a conjugated linoleic acid (cis-9, trans-11 CLA) with immunomodulatory properties, that correlated notably to the expansion of Bifidobacterium (p = 0.031; r = 0.052). Conclusions Our study demonstrates that ITF-prebiotic intake during 3 months decreases a fecal marker of intestinal inflammation in obese patients. Our data point to a potential contribution of microbial lipid-derived metabolites in gastro-intestinal dysfunction related to obesity. ClinicalTrials.gov Identifier NCT03852069 (February 22, 2019 retrospectively, registered).Funding Information
- Service Publique de Wallonie-Économie, Emploi, Recherche (1610365 and 1318148)
This publication has 49 references indexed in Scilit:
- Higher level of faecal SCFA in women correlates with metabolic syndrome risk factorsBritish Journal of Nutrition, 2012
- Interaction Between Obesity and the Gut Microbiota: Relevance in NutritionAnnual Review of Nutrition, 2011
- Targeting gut microbiota in obesity: effects of prebiotics and probioticsNature Reviews Endocrinology, 2011
- High cell density cultivation of Escherichia coli K4 in a microfiltration bioreactor: a step towards improvement of chondroitin precursor productionMicrobial Cell Factories, 2011
- Modulation of the gut microbiota by nutrients with prebiotic properties: consequences for host health in the context of obesity and metabolic syndromeMicrobial Cell Factories, 2011
- Weight loss during oligofructose supplementation is associated with decreased ghrelin and increased peptide YY in overweight and obese adultsThe American Journal of Clinical Nutrition, 2009
- Mechanism of conjugated linoleic acid and vaccenic acid formation in human faecal suspensions and pure cultures of intestinal bacteriaMicrobiology, 2009
- Conjugated linoleic acid: a functional nutrient in the different pathophysiological components of the metabolic syndrome?Current Opinion in Clinical Nutrition and Metabolic Care, 2006
- Bile salt biotransformations by human intestinal bacteriaJournal of Lipid Research, 2006
- Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel DiseaseScandinavian Journal of Gastroenterology, 1999